Your browser is no longer supported. Please, upgrade your browser.
MRK Merck & Co. Inc. daily Stock Chart
Merck & Co. Inc.
IndexDJIA S&P500 P/E34.54 EPS (ttm)1.57 Insider Own0.04% Shs Outstand2.82B Perf Week-2.96%
Market Cap152.27B Forward P/E14.29 EPS next Y3.79 Insider Trans0.00% Shs Float2.77B Perf Month-2.77%
Income4.44B PEG7.05 EPS next Q0.85 Inst Own75.20% Short Float1.04% Perf Quarter12.29%
Sales39.50B P/S3.86 EPS this Y-61.60% Inst Trans0.08% Short Ratio3.05 Perf Half Y-0.14%
Book/sh16.02 P/B3.38 EPS next Y2.08% ROA4.30% Target Price61.65 Perf Year-7.18%
Cash/sh4.77 P/C11.34 EPS next 5Y4.90% ROE9.60% 52W Range44.52 - 59.67 Perf YTD3.30%
Dividend1.84 P/FCF25.29 EPS past 5Y41.50% ROI6.40% 52W High-9.35% Beta0.67
Dividend %3.40% Quick Ratio1.30 Sales past 5Y-3.00% Gross Margin63.10% 52W Low21.49% ATR0.83
Employees68000 Current Ratio1.50 Sales Q/Q-2.50% Oper. Margin17.50% RSI (14)41.10 Volatility1.46% 1.36%
OptionableYes Debt/Eq0.59 EPS Q/Q-86.30% Profit Margin11.20% Rel Volume1.19 Prev Close54.81
ShortableYes LT Debt/Eq0.54 EarningsMay 05 BMO Payout114.60% Avg Volume9.40M Price54.09
Recom2.50 SMA20-3.18% SMA500.55% SMA2002.85% Volume11,208,418 Change-1.31%
Apr-06-16Initiated Societe Generale Buy $80
Jan-27-16Downgrade BofA/Merrill Buy → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $64 → $66
Nov-24-15Initiated Berenberg Hold
Nov-17-15Reiterated Argus Buy $70 → $65
Jun-17-15Initiated Piper Jaffray Neutral
Apr-29-15Reiterated UBS Buy $64 → $68
Apr-29-15Reiterated Argus Buy $66 → $70
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Jan-14-14Reiterated MKM Partners Buy $59 → $64
Jun-03-13Reiterated MKM Partners Buy $54 → $59
Apr-15-13Reiterated Barclays Overweight $45 → $60
Feb-04-13Reiterated MKM Partners Buy $51 → $52
Feb-04-13Reiterated Barclays Overweight $46 → $45
Nov-20-12Upgrade MKM Partners Neutral → Buy $47 → $51
Oct-17-12Reiterated MP Advisors Outperform $45 → $50
Jul-30-12Reiterated UBS Buy $45 → $50
Jul-13-12Upgrade MP Advisors Market Perform → Outperform $45
May-05-16 05:30PM  Stocks End Little Changed; Earnings, Oil Eyed Morningstar
05:13PM  Charts are bullish for health care: Technician Yahoo Finance
05:03PM  S&P 500, Dow end little changed ahead of jobs report; Nasdaq logs a loss at MarketWatch
04:01PM  The 4 Stocks That Edged the DJIA Down on Thursday at 24/7 Wall St.
03:16PM  [$$] Merck: Good Time to Buy at
01:25PM  Merck beats 1Q profit views with tight cost controls AP
01:10PM  Healthy biotech M&A? CNBC
12:53PM  Why Merck, Whole Foods Market & Other Stocks Are in Spotlight Today? at Insider Monkey
12:41PM  Regeneron Up As Eylea Beats Views; Merck Down As Lead Drugs Slip at Investor's Business Daily
12:20PM  Stocks Rise; Earnings, Oil Eyed Morningstar
12:01PM  7 Figures That Sum Up Merck & Co.'s First Quarter at Motley Fool
10:40AM  [$$] Merck Revenue Falls on Generic Competition at The Wall Street Journal
09:45AM  Pullback Among Chip Makers Is Latest Reason to Doubt the Rally --- Morning MoneyBeat at The Wall Street Journal
09:31AM  Stocks to Watch: Alibaba, Regeneron, Merck, AmerisourceBergen at The Wall Street Journal
09:18AM  Merck (MRK) Raises Outlook Following Q1 Earnings Beat Zacks
09:03AM  Merck (MRK) Stock Advances on Q1 Profit Beat, Raises 2016 Guidance at TheStreet
08:38AM  Merck's (MRK) Q1 Earnings Beat Estimates, Revenues Miss Zacks
07:53AM  Early movers: MRK, BABA, LB, TIME, BDX, AVP, DISCA, ABC, TSLA & more at CNBC
07:41AM  Merck's Q1 Adjusted Profit beats, But Revenue Miss, Narrows Adjusted EPS FY16 Forecast Benzinga
07:35AM  3 Big Pharma Stocks With Credible Threats to Their Blockbusters at 24/7 Wall St.
07:07AM  Q1 2016 Merck & Co Inc Earnings Release - Before Market Open CCBN
07:01AM  Merck quarterly profit up 18 percent Reuters
06:59AM  Merck beats profit expectations, bumps up full-year guidance range at MarketWatch
06:57AM  Merck quarterly profit up 18 pct Reuters
06:55AM  Merck beats 1Q profit forecasts AP
06:54AM  MERCK & CO., INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit EDGAR Online
06:49AM  Merck Quarterly Sales Slip Again as Some Older Drugs Disappoint at Bloomberg
May-04-16 04:06PM  Which Products Will Contribute to MRKs Earnings Growth in 1Q16? Market Realist
03:04PM  The Demise of the Market is Greatly Exaggerated Yahoo Finance Contributors
11:05AM  Which Products Will Offset Mercks Earnings Growth in 1Q16? Market Realist
10:05AM  Gilead Sciences: Feeling the Competitive Burn? at
09:30AM  The Zacks Analyst Blog Highlights: Zoetis, McKesson, Merck, Endo International and AmerisourceBergen Zacks
08:00AM  Merck to Present at the Deutsche Bank 41st Annual Health Care Conference Business Wire
May-03-16 07:15PM  [$$] Merck Earnings: What to Watch at The Wall Street Journal
06:28PM  Relypsa Taps Debt Market: Yeah, Thats Bullish Yahoo Finance Contributors
02:22PM  5 Data Points Wall Street Is Anxiously Awaiting in Merck's Q1 Report at Motley Fool
09:50AM  Drug Stocks Reporting Mid-Week: MRK, ABC, ENDP & More Zacks
09:09AM  AbbVies Viekira Pak Saw Weaker-than-Expected Performance Market Realist
08:03AM  Forget Bluebird Bio, Inc.: These 3 Stocks Are Better Buys at Motley Fool
07:06AM  What Do Analysts See in Merck & Co.s Future? Market Realist
12:34AM  Judge Allows More Evidence in Patent Dispute After Gilead Says Merck Attorney Lied at The Wall Street Journal
May-02-16 12:38PM  Gilead: What's Your Long Term Thesis? Yahoo Finance Contributors
11:46AM  Don't Give Up on Gilead Following a Weak Q1 at TheStreet
11:28AM  Medivation: Why a Takeover Just Got a Little Tougher at
11:12AM  Merck (MRK) Q1 Earnings: Can the Stock Pull a Surprise? Zacks
10:58AM  Earnings: Drug Makers Merck And Pfizer Report Q1 Results Benzinga
10:56AM  Pharma Giants Pfizer, Merck Take Center Stage at Forbes
10:13AM  Gilead Sciences to Merck: Not So Fast at
09:53AM  The 8 'Dogs Of The Dow' Outperformed The Average Through April at Forbes
09:20AM  Must-See Charts: How Healthy Are Bristol-Myers, Eli Lilly, Pfizer, Merck? at TheStreet
May-01-16 11:25AM  Merck And Pfizer Earnings: Will They Beat Expectations Again? Benzinga
Apr-29-16 08:27PM  Gilead Judge Re-Opens Case Amid Claim Merck Scientist Lied at Bloomberg
04:01PM  The 4 Stocks That Weighed on the DJIA Friday at 24/7 Wall St.
02:02PM  Here's Why Merck Has More Downside Ahead at TheStreet
11:16AM  Gilead Sciences, Inc. Reports Disappointing Q1 Harvoni Sales at Motley Fool
Apr-28-16 11:28PM  Gilead Disappoints, Harvoni Sales Drop 16% Yahoo Finance Contributors
08:01PM  9 Figures That Sum Up Gilead Sciences' First Quarter at Motley Fool
04:37PM  [$$] Gilead reports drop in Hepatitis C Drug Revenue at The Wall Street Journal
03:49PM  Traders show caution on Merck earnings optionMONSTER
11:07AM  What Developments Did Merck & Co. See during 1Q16? Market Realist
09:04AM  3 Healthcare Stocks Billionaires Love Right Now at Motley Fool
09:00AM  Will Gileads Run Come to an End this Quarter? Yahoo Finance Contributors
08:00AM  Christina Applegate and Merck Urge Insomnia Sufferers to Learn "Why They're So Awake" PR Newswire
Apr-27-16 06:04PM  Merck sex discrimination case could be collective action -judge Reuters
09:15AM  Major Pharma Short Interest Remains Mixed, With 1 Massive Drop at 24/7 Wall St.
08:00AM  Merck, the American Diabetes Association and America's Diabetes Challenge Celebrity Voices Unite to Take on National Health Epidemic PR Newswire
Apr-26-16 03:28PM  Will Merck & Co.s Revenue Recover Growth in 1Q16? Market Realist
03:28PM  Merck & Co.s 1Q16 Estimates Show Revenue Growth Market Realist
11:39AM  Journal of the American Medical Association Publishes Phase III Data from Allergic Asthma Trial with ALK's House Dust Mite SLIT-tablet, ACARIZAX® PR Newswire
08:00AM  New ranking crowns JPMorgan the top US company for diversity and inclusion at CNBC
Apr-25-16 04:25PM  5 Stocks With Bigger Dividends Than Merck & Co. at Motley Fool
10:58AM  Healthcare Q1 Earnings Look Solid: ETFs to Benefit Zacks
05:15AM  Management and Strategies Count Most Yahoo Finance Contributors
Apr-23-16 03:53PM  Five Healthcare Stocks Added to HealthInvest Partners Portfolio in Q1 at Insider Monkey
03:16PM  3 Things to Watch in Gilead Sciences, Inc.'s First-Quarter Results at Motley Fool
Apr-21-16 03:59PM  Why Relypsa Spiked Today and a Letter to the CEO Yahoo Finance Contributors
Apr-20-16 07:47AM  One and Done...and More! Yahoo Finance Contributors
07:00AM  New Treatment Now Available for Canadians with Metastatic Non-Small Cell Lung Cancer CNW Group
Apr-19-16 05:00PM  Merck Animal Health to Acquire Worldwide Rights to Whisper® Veterinary Stethoscope System Business Wire
02:05PM  Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meeting Business Wire
01:22PM  [$$] Roche 'very optimistic' on prospects for new cancer drugs at Financial Times
12:25PM  16 Reasons to Buy Merck and Never Sell at Motley Fool
09:06AM  What Do Analysts Recommend for Medivation?
08:21AM  [$$] Supply Chain Analytics Company FusionOps Grabs $25M at The Wall Street Journal
Apr-18-16 05:18PM  The Two Mercks Are Locking Horns in a Naming Trademark Spat at Fortune
11:07AM  Could Xtandis Use for Breast Cancer Be a Valuation Driver?
09:02AM  [$$] Clinical Development News, April 11-15 at The Wall Street Journal
08:00AM  Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA® (pembrolizumab) in Classical Hodgkin Lymphoma (cHL) Business Wire
05:15AM  Disappointed over G-20 and Doha Meetings
Apr-17-16 03:27PM  Relypsa's Wild Rumors and the Facts that Were Ignored
Apr-16-16 09:36AM  Valeant vs. Abbott Labs: Which Is Better for My Portfolio? (VRX, ABT) at Investopedia
01:00AM  Merck Announces Results From Phase 3 Studies of ZEPATIER (Elbasvir and Grazoprevir) in Chronic Hepatitis C Patient Populations at The International Liver Congress Business Wire
Apr-15-16 07:41PM  Merck CEO Kenneth Frazier Sells 131,040 Shares
11:22AM  [$$] Best Bets in Biopharma at
Apr-14-16 05:45PM  New tests for choosing right hep C drug could save money
04:30PM  Stand Up To Cancer launches new industry-supported research program at
04:01PM  The 4 Stocks That Buoyed the DJIA on Thursday at 24/7 Wall St.
02:21PM  Stocks fight for gains after earnings disappoint, jobless claims drop at MarketWatch
12:20PM  Drug giant plots Peninsula expansion, 150 more jobs at
11:20AM  Merck Offers Positive Data from Comparative Trial on Zepatier
Merck & Co., Inc. provides health care solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also provides neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for the treatment of C. difficile, and vaccines against bacterial and viral disease in fish. Additionally, the company offers companion animal products, such as ointments for acute and chronic otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HARRISON WILLIAM B JRDirectorApr 13Option Exercise34.445,000172,20016,400Apr 13 03:03 PM
WEEKS WENDELL PDirectorNov 04Option Exercise34.445,000172,2005,100Nov 04 04:37 PM
WEEKS WENDELL PDirectorNov 04Sale55.535,000277,669100Nov 04 04:37 PM
FRAZIER KENNETH CChairman, President & CEOOct 29Option Exercise35.0918,666654,990456,902Oct 30 04:58 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerOct 29Option Exercise36.5637,3131,364,16357,008Oct 29 04:23 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerOct 29Sale55.0837,3132,055,33419,695Oct 29 04:23 PM
FRAZIER KENNETH CChairman, President & CEOOct 29Sale54.6918,6661,020,758438,236Oct 30 04:58 PM
WENDELL PETER CDirectorOct 28Option Exercise34.445,000172,2006,000Oct 28 02:44 PM
WENDELL PETER CDirectorOct 28Sale54.855,000274,2371,000Oct 28 02:44 PM
Holston Michael JEVP, General CounselAug 01Option Exercise0.0022,584062,584Aug 04 02:41 PM
Golestani ClarkEVP & Chief Info OfficerJul 31Option Exercise39.8335,5421,415,54643,994Aug 04 02:41 PM
Golestani ClarkEVP & Chief Info OfficerJul 31Sale59.0931,8311,880,80512,163Aug 04 02:41 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 11Sale60.4410,634642,7680May 11 05:48 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 08Option Exercise35.2846,2081,630,39670,353May 11 01:33 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 08Sale60.9938,3682,339,94931,985May 11 01:33 PM